merged_alzheimers-treatment-kisunla-donanemab.txt

<other>Analyzing the article to answer each question based solely on its content.</other>
<question_number>1</question_number>
<answer>significant safety risks including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>it might discourage patients from participating in trials for potentially better treatments and slow progress</answer>
<question_number>3</question_number>
<answer>no correlation in any of their studies</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>patients can stop treatment after amyloid is cleared, reducing overall cost</answer>
<question_number>6</question_number>
<answer>might discourage patients from participating in other clinical trials</answer>
<question_number>7</question_number>
<answer>monthly infusions and ability to stop treatment after amyloid clearance</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>patients with intermediate tau levels declined more slowly than those with high levels</answer>
<other>All answers derived exclusively from the provided article text.</other>